Last reviewed · How we verify

Bioverativ Therapeutics Inc. — Portfolio Competitive Intelligence Brief

Bioverativ Therapeutics Inc. pipeline: 4 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 4 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Enjaymo SUTIMLIMAB marketed Classical Complement Pathway Inhibitor [EPC] Complement C1s subcomponent Immunology 2022-01-01
rFVIIIFc rFVIIIFc marketed Recombinant clotting factor (Factor VIII replacement therapy) Factor VIII / FcRn (neonatal Fc receptor) Hematology
Advate® Advate® marketed
FIX FIX marketed Recombinant coagulation factor replacement Factor IX (coagulation cascade) Hematology
BIIB031 (rFVIIIFc) BIIB031 (rFVIIIFc) phase 3 Recombinant clotting factor (Factor VIII Fc fusion) Factor VIII / coagulation cascade Hematology
FVIII (PK subgroup only) FVIII (PK subgroup only) phase 3 Coagulation factor replacement Factor VIII (coagulation cascade cofactor) Hematology
Factor VIII (rFVIIIFc) Factor VIII (rFVIIIFc) phase 3 Recombinant clotting factor Factor VIII / Intrinsic tenase complex Hematology
Factor IX (rFIXFc) Factor IX (rFIXFc) phase 3 Recombinant clotting factor (Factor IX fusion protein) Factor IX (coagulation cascade) Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Wyeth is now a wholly owned subsidiary of Pfizer · 3 shared drug classes
  2. Beijing Children's Hospital · 1 shared drug class
  3. Hoffmann-La Roche · 1 shared drug class
  4. Kedrion S.p.A. · 1 shared drug class
  5. Baxalta now part of Shire · 1 shared drug class
  6. Octapharma · 1 shared drug class
  7. RECORDATI RARE DISEASES, INC. · 1 shared drug class
  8. Takeda · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Bioverativ Therapeutics Inc.:

Cite this brief

Drug Landscape (2026). Bioverativ Therapeutics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioverativ-therapeutics-inc. Accessed 2026-05-17.

Related